Within a year, we proudly introduced our groundbreaking products: “Nitrophage Forte ^TM” for Uremic pruritus in CKD and “Nitrophage™” for Minimal Hepatic Encephalopathy. This marked our expansion, including the establishment of our Bangalore office.

In 2017, a major milestone was achieved with the introduction of India’s first synbiotic. The NIFTYY trial published in the prestigious IJBCP validated Synbiotics’ role in managing inflammatory markers, revolutionizing the field.

In 2018, our dedication resulted in completing Aminase™ pre-clinical studies and a successful clinical trial, leading to its launch. Meanwhile, Enzobiotics™ made significant progress, advancing to clinical trials across India.

In 2019, Mylin Biotech entered critical care with Protinace 98™ launch and focused on IP protection with Aminase™ patents and ongoing clinical trials for Enzobiotics™

In 2020, Mylin Biotech’s R&D efforts paid off with the Enzotein™ clinical trial publication in the International Journal of Nephrology & Therapeutics. We gained global recognition with the first-ever Indian trial presentation at the American Society of Nephrology conference in Washington. We also filed patents for Enzotein and Enzobiotic to protect our novel solutions.

In 2021, our Enzobiotic pre-clinical study publication solidified our pioneering status. It also paved the way for the eagerly anticipated Enzobiotic clinical trial results, shaping the future of healthcare.

In 2022, we reinforced our commitment to high-quality probiotic therapies by opening a state-of-the-art facility in Bangalore, optimizing probiotic development and manufacturing for superior product quality and efficacy.